Carey Danis & Lowe Pradaxa lawyers are currently following the Pradaxa multi-district litigation (MDL) in Illinois. The Pradaxa MDL is In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL no. 2385. The Pradaxa MDL is being heard in the U.S. District Court for the Southern District of Illinois, and is presided over by Chief Judge David R. Herndon.
According to Carey Danis & Lowe Pradaxa lawyers, the Pradaxa MDL 2385 continues to move forward with pre-trial proceedings. As documented in minutes from the latest Pradaxa MDL status conference, the plaintiffs’ counsel is currently working on deposition scheduling. Also, the defendants’ counsel supplied an updated on discovery production.
The next Pradaxa MDL status conference is scheduled for May 14, 2013.
At the time of writing, the Pradaxa MDL 2385 comprised 486 cases. Pradaxa lawyers at Carey Danis & Lowe are interested to see if this case number will be affected by the recent news of Pradaxa attaining blockbuster status in the pharmaceutical world.
Reuters recently reported that Pradaxa sales brought in $1.43 billion in 2012. Though sales of the anticoagulant drug appear to be steady, the number of Pradaxa lawsuits being filed against Boehringer Ingelheim citing serious bleeding injuries and even death continue to increase as well.
Carey Danis & Lowe Pradaxa lawyers encourage individuals who have been injured by Pradaxa to contact our law firm today for a free legal evaluation about Pradaxa cases.Pharmaceutical litigation, Pradaxa